Literature DB >> 7175626

Bilateral macular infaction in SS disease.

J C Merritt, J M Risco, J P Pantell.   

Abstract

A 10-year-old Afro-American female with SS disease presented with a history of painless loss of vision (RE) of 26 hours duration. Sequential fluorescein angiography revealed bilateral parafoveal occlusions and evidence of prior vaso-occlusions in each eye. Initial hydration therapy with dextrose 5% and 1/4 normal saline was followed within eight hours by transfusion with two units of packed red blood cells. Patency was restored to the occluded arterioles with return of normal acuity in LE, though the vision remains at hand motions in the RE. Sudden loss of central acuity in sickle hemoglobinopathies may result from vaso-occlusion in terminal arterioles near the foveal avascular zone. Therefore a reduced number of permanently irreversibly sickled red blood cells may prevent these macular infarcts.

Entities:  

Mesh:

Year:  1982        PMID: 7175626     DOI: 10.3928/0191-3913-19820901-21

Source DB:  PubMed          Journal:  J Pediatr Ophthalmol Strabismus        ISSN: 0191-3913            Impact factor:   1.402


  4 in total

1.  Conjunctival microvascular haemodynamics in sickle cell retinopathy.

Authors:  Ali Kord Valeshabad; Justin Wanek; Ruth Zelkha; Jennifer I Lim; Nicole Camardo; Bruce Gaynes; Mahnaz Shahidi
Journal:  Acta Ophthalmol       Date:  2014-11-27       Impact factor: 3.761

2.  Macular infarction associated with reactive arthritis.

Authors:  Ju-Young Kim; Jong-Hyuck Lee; Ie-Na Yoon
Journal:  Korean J Ophthalmol       Date:  2010-10-05

3.  Monitoring retinal pathology and cerebral injury in sickle cell disease using spectral-domain optical coherence tomography in pediatric patients.

Authors:  Jing Jin; Vinay Kandula; Robin E Miller
Journal:  Pediatr Blood Cancer       Date:  2021-03-31       Impact factor: 3.838

4.  Retinal Oxygen Delivery and Metabolism in Healthy and Sickle Cell Retinopathy Subjects.

Authors:  Mahnaz Shahidi; Anthony E Felder; Ou Tan; Norman P Blair; David Huang
Journal:  Invest Ophthalmol Vis Sci       Date:  2018-04-01       Impact factor: 4.799

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.